Thus, developing an innovative anti-SIAH-based anti-K-RAS strategy will reveal novel SIAH pathway biomarker(s) as well as logical and potent SIAH-centered drug target(s) to eradicate and control pancreatic cancer in the future (Figure 2B). Here, KRAS is linked to familial pancreatic carcinoma.